Viewing Study NCT00227305



Ignite Creation Date: 2024-05-05 @ 12:03 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00227305
Status: COMPLETED
Last Update Posted: 2013-01-08
First Post: 2005-09-27

Brief Title: Quetiapine Fumarate SEROQUEL in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A 26-week Multicenter Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate SEROQUEL Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia Abbreviated
Status: COMPLETED
Status Verified Date: 2013-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ANCHOR 150
Brief Summary: The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate SEROQUEL in the treatment of adolescent patients with schizophrenia and bipolar I disorder
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None